Priya Ramanathan

59F · SH-10326APP

Atherosclerotic (post-MI) · GP (part-time)

Next consult

Fri 17 Apr, 14:30

Positive· p 0.76Trending better

Trajectory headline

Secondary-prevention regimen is working. Residual risk is Lp(a)-driven; consider PCSK9 if LDL not at target at next review.

Model priority

Positive zone

Biggest single change you could makeStatin · high-intensity → −50% (LDL-C)

Patient Context Card · AIME

Brief

Trajectory-grounded orientation for today's appointment.

Nine months post-MI. Trajectory is improving on current regimen. Focus: residual Lp(a) risk.

Trajectory narrative

Priya had an anterior NSTEMI in July 2025 managed with PCI. She is on full secondary-prevention therapy and the trajectory shows measurable improvement across the atherosclerotic axis. LDL-C is on target. The remaining signal is Lp(a), not yet measured, which modulates residual ASCVD risk and could justify PCSK9 escalation if elevated.

Active concerns

LDL-C 1.6 mmol/L (at target)
Residual risk uncharacterised (Lp(a) pending)
BP well-controlled, home average 122/76

Suggested consultation focus

Check adherence and side-effect burden
Order one-off Lp(a)
Reinforce cardiac rehab progression

Supporting record context

Current medications

Atorvastatin 80mg · Ezetimibe 10mg · Bisoprolol 5mg · Ramipril 5mg · Aspirin 75mg · Ticagrelor 90mg BD

Allergies

NKDA

Event

Anterior NSTEMI 2025-07; PCI to LAD; EF 48% on discharge echo

For demonstration purposes. Not a diagnostic tool.

Horizon-1 · Syndrome activation

Latent clinical states

Output of the dynamic hypergraph. Direction = trajectory on that axis.

Atherosclerotic (controlled)

0.58

Metabolic (mild)

0.34

For demonstration purposes. Not a diagnostic tool.